TrialInternational journal of hematology2004

A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002.

Tomohiro Kinoshita et al.PubMed ↗Publisher ↗

No numbers read from the abstract.